Vusolimogene oderparepvec clinical trials
Also written RP1.
How each study uses vusolimogene oderparepvec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the vusolimogene oderparepvec studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 6 Aug 2026 · TUDRIQEV · BLA 125827 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 4
Replimune, Inc. (2) · Sherrif Ibrahim (1) · Replimune Inc. (1) · Varun Monga, MBBS (1) · Yana Najjar (1) · Institut Curie (1)
Studies
Open first, then newest update. How each study uses vusolimogene oderparepvec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaRecruitingPhase 2Varun Monga, MBBSNCT06898970Written as Vusolimogene Oderparepvec (VO)
- VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]RecruitingPhase 3Replimune, Inc.NCT06264180Written as Vusolimogene Oderparepvec
- RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node MetastasisRecruitingEarly Phase 1Yana NajjarNCT06216938Written as Vusolimogene oderparepvec (RP1)
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)Active, not recruitingPhase 2Replimune, Inc.NCT03767348Written as RP1
- Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.Active, not recruitingPhase 1/2Sherrif IbrahimNCT05858229Written as RP1
- "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast CancerTerminatedPhase 1/2Institut CurieNCT06067061Written as Atezolizumab + RP1
- Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin CancerActive, not recruitingPhase 2Replimune Inc.NCT04050436Written as RP1
Codes
What other systems call vusolimogene oderparepvec · ClinicalTrials.gg INT014803
- UNII (FDA) 45KLN7N6UVVUSOLIMOGENE ODERPAREPVECOne source FDA
- NCI Thesaurus C158074Vusolimogene OderparepvecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 45KLN7N6UV | VUSOLIMOGENE ODERPAREPVEC | One source FDA |
| NCI Thesaurus | C158074 | Vusolimogene Oderparepvec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.